2024年4月此乱象被相关媒体曝光后，北京铁检院运用大数据法律监督模型摸排线索，于10月立案调 查，通过线上模拟下单、线下走访查明，并制发检察建议。针对诊所提供药品行为的法律性质争议，该 院召开公开听证会厘清定性，诊所与用户之间实质法律关系应为"销售"而非"诊疗"，应由市场监督管理 部门进行监管，卫生健康部门作为医疗机构的主管部门，应当与市场监督管理部门形成监管合力。 听证会后，北京市市场监督管理部门和卫生健康部门到涉案诊所开展联合检查。市场监督管理部门现场 制发《行政告诫书》，要求诊所全面整改，同时开展专项整治，成效显著：累计检查医疗机构、药品网 络销售企业161家，抽查药品208种，约谈企业12家，查处药品案件21件，推动平台完成40批次药品抽检 等。 为进一步提升治理效能，北京铁检院推动相关行政机关签订《关于加强网络禁止销售药品监管行政执法 协作备忘录》，明确具体违法情形的查处职责，约谈平台加强监管，督促其加强入驻商家资质审核与行 为监管，增加交易风险提示，预防违法行为发生。 中国经济网北京2月9日讯客服自动问答、无需线下就诊，仅提供付款核销码就能收到网络禁售药品？2 月9日，最高检举行新闻发布会通报" ...

南都讯 记者刘嫚 发自北京 电商平台部分诊所通过虚假问诊形式变相销售网络禁售药品，存药品滥用风 险，检察机关运用大数据法律监督模型发现线索，查清违法行为，推动将医疗机构销售网络禁售药品行 为纳入监管视野，促进互联网药品经营规范化。2月9日，最高人民检察院举行新闻发布会，发布"食药 安全益路行"检察公益诉讼监督典型案例，上述案例入选。 2024年10月28日，北京铁检院向某区市场监督管理部门制发检察建议，建议其依法履行监督管理职责， 建立健全长效工作机制，加强对辖区内网络售药的监督管理。收到检察建议后，行政机关高度重视，但 对诊所提供药品行为的法律性质存在争议。北京铁检院召开公开听证会，医药领域法学专家、相关市场 监督管理部门、卫生健康管理部门及电子商务平台代表研讨后一致认为：自动问答模仿问诊形式，但不 具有疾病诊断的实质内容，诊所向用户提供药品的行为与药品经营者"药品在线下单+快递到家"的网络 销售模式一致，诊所与用户之间实质法律关系应为"销售"而非"诊疗"，应由市场监督管理部门进行监 管，卫生健康部门作为医疗机构的主管部门，应当与市场监督管理部门形成监管合力。 听证会后，前述两部门到涉案诊所开展联合检查。市 ...

Core Points - The criminal Zhou Liren was executed for the poisoning case at Xiangtan University, where he intentionally poisoned his roommates, resulting in one death [1][2] - Zhou Liren had a background in a field related to the toxic substance colchicine, which he used to commit the crime [1][2] Summary by Sections - **Incident Overview** - Zhou Liren, a master's student at Xiangtan University, had conflicts with his roommates, leading to his decision to poison them [1] - He purchased colchicine and secretly added it to a shared food item, resulting in the death of Zhang [1][2] - **Legal Proceedings** - The court found Zhou guilty of intentional homicide, emphasizing his premeditated actions and the severe consequences of his crime [2] - The court highlighted Zhou's attempt to conceal evidence and delay medical treatment for the victim, which contributed to the fatal outcome [2]

Core Viewpoint - Changchun High-tech, once known as "Northeast Medicine King," has faced a significant decline, with its market value evaporating by 160 billion yuan and stock prices plummeting by 84%. However, the approval of a new gout drug, "Jinbeixin," and plans for a Hong Kong IPO have sparked hopes for a turnaround [1][3]. Group 1: R&D and IPO Strategy - Over the past three years, Changchun High-tech has invested more than 6 billion yuan in R&D, with the R&D expense ratio soaring to nearly 20% in 2024. The company has increased its workforce by 2,518 employees, primarily in R&D and self-immune drug promotion [3]. - The company announced the preparation for an H-share listing on July 1, aiming to open up overseas financing channels to alleviate the financial pressure from its 6 billion yuan R&D "black hole" [3]. - Despite the low liquidity in the Hong Kong market, the policy allowing unprofitable innovative drug companies to list provides a lifeline for Changchun High-tech [3]. Group 2: New Drug Approval and Market Challenges - The National Medical Products Administration approved the new drug "Jinbeixin" for acute gouty arthritis, offering new hope for Changchun High-tech. Clinical data shows that it can significantly reduce pain and recurrence risk for patients [6]. - However, the market path for Jinbeixin is fraught with challenges, including competition from domestic rivals and pricing pressures. The expected price of Jinbeixin is 2,000 yuan per injection, which may deter patients if it is not included in medical insurance [7]. Group 3: Diversification Attempts and Lessons Learned - Jinbeixin is not the first attempt at diversification for Changchun High-tech. The company's shingles vaccine, launched in 2022, initially showed promise but saw a revenue drop from 1.82 billion yuan in 2023 to 1.23 billion yuan in 2024, with a 53% decline in net profit [8]. - The decline in the shingles vaccine's market share was attributed to its lower efficacy compared to competitors' products, highlighting the challenges of diversification [8]. Group 4: Decline of Growth Hormone and Future Outlook - The company's growth hormone product, which once held a 75% market share, has seen its revenue significantly impacted by price reductions due to national medical procurement policies, leading to a 43% drop in net profit in 2024 [9]. - Looking ahead, Changchun High-tech has 24 products in clinical stages across various fields, including oncology and reproductive health, indicating potential for future growth if successful in diversifying its product offerings [10].

Core Viewpoint - The article discusses the significant disparity between the pharmaceutical markets for diabetes and gout, highlighting the large patient base for gout yet the lack of blockbuster drugs in this area despite its similar chronic nature to diabetes [3][4][18]. Group 1: Patient Demographics and Disease Impact - There are approximately 1 billion people globally suffering from high uric acid and gout, making it the second largest metabolic disease after diabetes [4][6]. - In China, there are 177 million individuals with high uric acid levels and 14.66 million gout patients, indicating a substantial patient population [6]. - The pathophysiology of gout involves an imbalance in purine metabolism, leading to elevated uric acid levels and subsequent crystal deposition, which can cause severe inflammation [6][7]. Group 2: Treatment Landscape and Challenges - Current gout treatments are limited, with no drug achieving annual sales exceeding $1 billion, contrasting sharply with diabetes medications [4][10][18]. - Existing gout medications face significant safety concerns, including severe side effects and low treatment adherence among patients, with many relying solely on pain relief rather than long-term management [10][11][15]. - The complexity of gout's pathogenesis complicates drug development, as effective treatment requires addressing multiple metabolic pathways [7][10]. Group 3: Market Dynamics and Future Outlook - The global market for gout medications is projected to be only $3.3 billion by 2024, while the diabetes drug market approaches $100 billion, influencing pharmaceutical companies to prioritize diabetes research [18]. - Despite the challenges, domestic pharmaceutical companies in China are showing innovation in gout treatment, with several drugs in advanced clinical stages, suggesting potential growth in this market [19]. - The article posits that the focus on gout treatment could lead to a "marginal revolution" in medicine, similar to past breakthroughs in other areas [19].